GHP Investment Advisors Inc. Purchases 1,193 Shares of Johnson & Johnson (NYSE:JNJ)

GHP Investment Advisors Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 2.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 54,704 shares of the company’s stock after buying an additional 1,193 shares during the period. GHP Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $7,911,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. AMF Tjanstepension AB lifted its holdings in shares of Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after purchasing an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC purchased a new stake in Johnson & Johnson in the third quarter valued at about $209,000. Wealth Group Ltd. acquired a new stake in Johnson & Johnson in the third quarter worth about $213,000. Brown Miller Wealth Management LLC grew its stake in shares of Johnson & Johnson by 2.3% during the third quarter. Brown Miller Wealth Management LLC now owns 19,673 shares of the company’s stock worth $3,188,000 after acquiring an additional 436 shares during the last quarter. Finally, Mechanics Bank Trust Department increased its holdings in shares of Johnson & Johnson by 0.5% during the third quarter. Mechanics Bank Trust Department now owns 57,568 shares of the company’s stock valued at $9,329,000 after acquiring an additional 272 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3 %

Shares of Johnson & Johnson stock opened at $153.10 on Monday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market cap of $368.61 billion, a P/E ratio of 23.02, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The firm has a 50-day simple moving average of $147.42 and a two-hundred day simple moving average of $156.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $2.29 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.24%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several research analyst reports. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Guggenheim increased their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.